Building AI-first companies
We work with leadership teams to rethink how a company reaches its market, runs its operations, and makes decisions. AI adoption needs to serve the business across go-to-market, internal workflows, and governance.
Ilya Ryabinin · Silicon Wadi
Silicon Wadi is led by Ilya Ryabinin, an investor, board director, and AI leader.
Our work connects biotech investment research with the companies and technology we build. BioDosier is at the centre of that work.

The science, the business,
and the investment thesis.
Biotech investing means understanding both clinical evidence and commercial reality. BioDosier brings that research together: the trials, the company’s finances, and the events that could change the thesis.
AI supports the research. Investment judgment stays with the investor.
Visit BioDosier (opens in a new tab)Private research desk · Access for approved accounts
Assess the clinical evidence
Trial design / Clinical results / Safety data
Understand the financial position
SEC filings / Cash burn / Financing terms
Track what could change
Trial readouts / FDA decisions / Thesis conditions
Also taking shape
Support for everyday life.
Directed by the person living it.
We’re developing a personal companion to help people living with dementia maintain independence. Support for memory, daily routines, and staying connected starts with the individual’s choices.
Discover Dementia CoPilot (opens in a new tab)Operating & board roles
Alongside our ventures, Ilya’s work spans AI leadership and startup board roles.
We work with leadership teams to rethink how a company reaches its market, runs its operations, and makes decisions. AI adoption needs to serve the business across go-to-market, internal workflows, and governance.
Our board work brings an independent perspective to priorities, resources, and execution. We help leadership assess new opportunities while staying focused on the company’s core objectives.
Get in touch
For introductions, our ventures, or a shared investment interest.